Most people have heard of cholesterol checks and blood pressure readings as the go to measures for heart health. But a simple urine test could flag cardiovascular risk years before symptoms ever appear. Fewer people know that a routine urine test, one that measures a protein called albumin, can tell us something profound about the state of your cardiovascular system. That test is the urine albumin to creatinine ratio, or ACR, and the evidence behind it as a cardiac risk marker is growing year on year.
As a pharmacist, I want to walk you through what this test actually measures, why it matters for your heart, and why your GP might start, or already has started, including it in your annual review.
What Is Urine ACR and Why Does It Exist?
Your kidneys are filtration units. Every minute, they process roughly 1.3 liters of blood, removing waste while holding on to proteins your body needs. Albumin is one of those proteins, large enough that healthy kidneys should retain almost all of it. When small but detectable amounts start leaking into the urine, it signals that the kidney’s filtration barrier has been damaged.
Importantly, this kind of damage rarely happens in isolation. The same processes that injure the kidneys, chronic inflammation, endothelial dysfunction, oxidative stress, and microvascular disease, are at work in the coronary arteries, too. This is why a urine ACR result is never just a kidney number. It is a window into the health of your entire vascular system.
The ACR is expressed as milligrams of albumin per millimole of creatinine (mg/mmol) in UK laboratories, while some countries, particularly the United States, report it as milligrams per gram (mg/g).
• Normal range: Below 3 mg/mmol (below 30 mg/g) is considered normal
• Mildly elevated albuminuria (previously microalbuminuria): Between 3 and 30 mg/mmol (30–300 mg/g)
• Moderately to severely elevated albuminuria: Above 30 mg/mmol (above 300 mg/g), a finding that warrants prompt clinical attention
In simple terms: regardless of the unit used, even small increases above the normal range can signal early vascular and kidney stress.
The Evidence (What the Research Actually Shows)
This is not a niche theory. The cardiovascular significance of raised urine ACR has been demonstrated in some of the largest epidemiological studies ever conducted.
The HOPE study, published in the New England Journal of Medicine (2001), followed over 9,000 high risk patients and found that even mildly elevated albuminuria independently predicted major cardiovascular events including myocardial infarction, stroke, and cardiovascular death, and this relationship held even after adjusting for traditional risk factors such as blood pressure, cholesterol, and diabetes status.
A landmark meta-analysis published in The Lancet (Matsushita et al., 2010), drawing on data from over 100,000 individuals across the CKD Prognosis Consortium, confirmed that both reduced kidney function and elevated albuminuria are independently associated with increased cardiovascular mortality. Crucially, the risk gradient was continuous, there was no safe threshold below which elevated ACR carried zero risk. Even mild elevations were linked to a measurable rise in cardiovascular risk.
The ADVANCE trial, reported in the New England Journal of Medicine (2008), specifically examined patients with type 2 diabetes and found that albuminuria was among the strongest predictors of cardiovascular events in that population, outperforming several conventional markers when analyzed in combination with kidney function measures.
More recently, data from the EMPA-REG OUTCOME demonstrated that SGLT2 inhibitors, medications like empagliflozin, reduced albuminuria alongside their cardiovascular benefits, lending further weight to the biological relationship between albumin leakage and heart disease. This overlap is not incidental; it reflects shared underlying vascular damage.
Why Does Albuminuria Signal Heart Risk Specifically?
This is the question patients often ask me, and it is a fair one. The short answer is endothelial dysfunction.
The endothelium is the single cell lining of every blood vessel in your body. When it is healthy, it regulates vascular tone, prevents clotting, and suppresses inflammation. When it is under chronic stress, from high blood sugar, sustained high blood pressure, smoking, or dyslipidaemia, it becomes leaky, inflamed, and dysfunctional.
The glomerular filtration barrier in the kidney contains endothelial cells. When systemic endothelial dysfunction develops, the kidney’s filtration layer is one of the first places to show measurable damage, because its cells are exposed to enormous haemodynamic stress throughout the day. Albumin leaking into the urine is therefore an early biomarker of the same endothelial injury that, in the coronary arteries, eventually leads to atherosclerotic plaque formation, plaque rupture, and acute myocardial infarction.
Put simply, if the vessels in your kidneys are leaking, your cardiovascular system may already be under strain.
Who Should Have This Test?
Clinical guidelines in many countries, including those from the UK’s National Institute for Health and Care Excellence, recommend urine ACR testing annually in anyone with type 2 diabetes, type 1 diabetes, hypertension, chronic kidney disease, or a high cardiovascular risk score. In the UK, the National Health Service also includes it as part of routine diabetes and kidney health reviews.
However, the clinical picture is shifting. Emerging guidance increasingly supports ACR testing as a broader cardiovascular screening tool, not just a kidney specific measure, particularly in individuals over 50, those with a family history of cardiovascular or renal disease, people with obesity or metabolic syndrome, and South Asian or Black African populations who carry a disproportionately higher burden of both CKD and cardiovascular disease.
In practical terms, you should consider asking about this test if you fall into any of these groups,
• Type 2 or type 1 diabetes
• High blood pressure
• Age over 50
• Family history of heart or kidney disease
• Overweight or metabolic syndrome
• South Asian or Black African background
If none of those apply to you but you have not had a recent health check, it is worth asking your healthcare provider whether a urine ACR is included. In many settings it is, and it takes a single urine sample collected at home to get a result.
What Happens If Your ACR Is Elevated?
An elevated result does not mean you are about to have a heart attack. What it means is that your risk profile needs a careful look, and that there is likely an opportunity to act.
Your GP will typically repeat the test on two further occasions before making a clinical decision, since transient elevations can occur with,
• Urinary tract infections
• Fever
• Strenuous exercise
• Dehydration
A consistently elevated ACR, however, should prompt a full review, including,
• Blood pressure optimization
• HbA1c assessment (if relevant)
• Lipid management
• Potential introduction of renin angiotensin system blockade, ACE inhibitors or ARBs, which have strong evidence for both reducing albuminuria and lowering cardiovascular risk.
Lifestyle measures also matter substantially here,
• Smoking cessation
• Sodium restriction
• Regular physical activity
• Achieving a healthy weight
have all been shown to reduce albuminuria in clinical studies. These are not just general health tips; they directly influence vascular function and protein leakage in the kidneys.
SGLT2 inhibitors and GLP-1 receptor agonists, medication classes increasingly used in type 2 diabetes and, more recently, in heart failure and obesity, have also demonstrated meaningful reductions in ACR alongside their cardiorenal benefits, as evidenced by trials such as CREDENCE trial and DAPA-CKD trial.
The Bottom Line
Urine ACR is not glamorous. It does not generate headlines in the way that cholesterol lowering drugs or cardiac imaging do. But as a pharmacist who works with patients managing long term conditions daily, I would argue it is one of the most underused early warning tools in general practice.
A small amount of protein in the urine, something detectable in a standard morning sample, can reveal that your blood vessels are under stress long before symptoms appear and long before a cardiac event occurs. That early signal creates a critical window to intervene.
If you have risk factors for heart disease and have never had a urine ACR checked, bring it up at your next appointment. It is one of the simplest tests in medicine, and the evidence supporting its clinical value has never been stronger.
FAQs
Q1. What is a normal urine ACR result?
A result below 3 mg/mmol (below 30 mg/g) is considered normal. Between 3 and 30 mg/mmol (30–300 mg/g) indicates mildly elevated albuminuria, and anything above 30 mg/mmol (above 300 mg/g) is classed as moderately to severely elevated. Your healthcare provider will interpret your result in the context of your overall health picture.
Q2. Can a high urine ACR definitely mean I will have a heart attack?
No, An elevated ACR does not predict a heart attack with certainty, it indicates that your cardiovascular risk profile warrants closer attention. Many people with raised ACR levels live without ever experiencing a cardiac event, particularly when the underlying risk factors are identified and managed promptly.
Q3. How is the urine ACR test done?
It is straightforward. You collect a urine sample, usually the first of the morning, in a small container provided by your GP surgery. No needles, no fasting, no hospital visit required. The sample is sent to a laboratory, and results are typically available within a few days.
Q4. Does diabetes automatically mean my ACR will be high?
Not automatically, but diabetes is one of the leading causes of elevated albuminuria due to the damage high blood glucose causes to the kidney’s filtration vessels. This is why annual ACR testing is a standard part of diabetes care.
Q5. Can lifestyle changes actually lower my ACR result?
Yes, meaningfully so. Stopping smoking, reducing salt intake, achieving a healthy weight, and staying physically active have all been shown in clinical studies to reduce albumin excretion. In some cases, improvements in ACR are measurable within weeks of sustained lifestyle change.
Q6. Will I need medication if my ACR comes back elevated?
Not necessarily on first result. Your GP will usually repeat the test twice more to confirm the finding. If consistently elevated, treatment options, such as blood pressure medication or, where appropriate, SGLT2 inhibitors, may be discussed based on your full clinical picture.
Q7. Is urine ACR testing widely available?
Yes, It is routinely offered to people with diabetes, hypertension, and chronic kidney disease as part of regular health reviews. If you have cardiovascular risk factors but have not been offered the test, it is worth asking your healthcare provider whether it is appropriate for you.
Call to Action
A simple urine test could reveal what routine heart checks might miss. If you found this article helpful, share it with someone who would benefit, especially those managing diabetes or blood pressure, and explore more evidence-based health guides at PharmaHealths. Early awareness can make a measurable difference.
Disclaimer
This article has been written for general informational purposes only and reflects evidence available at the time of publication. It is not intended to replace professional medical advice, diagnosis, or treatment. Urine ACR results should always be interpreted by a qualified healthcare professional in the context of your individual medical history. If you have concerns about your kidney function, cardiovascular health, or any symptoms discussed in this article, please contact your GP or a qualified healthcare provider. Do not delay seeking medical advice based on content read here.
References
• Gerstein HC et al. JAMA (2001), Albuminuria linked to cardiovascular outcomes
• Matsushita K et al. The Lancet (2010), Large meta-analysis on ACR and mortality risk
• ADVANCE Collaborative Group. N Engl J Med (2008), Diabetes and vascular outcomes
• Zinman B et al. N Engl J Med (2015), SGLT2 inhibitors and cardiovascular outcomes
• Perkovic V et al. N Engl J Med (2019), Renal outcomes with canagliflozin
• Heerspink HJL et al. N Engl J Med (2020), Dapagliflozin in CKD
• NICE CG182 (2021), CKD assessment and management guidelines
